(0.19%) 5 141.00 points
(0.12%) 38 486 points
(0.30%) 17 899 points
(-0.10%) $83.77
(1.25%) $1.947
(0.23%) $2 352.60
(0.54%) $27.68
(1.84%) $939.10
(-0.17%) $0.933
(-0.24%) $11.00
(-0.27%) $0.798
(1.24%) $93.01
@ $11.35
発行日: 14 2月 2024 @ 23:30
リターン: -2.56%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 3.37 %
Live Chart Being Loaded With Signals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers...
Stats | |
---|---|
本日の出来高 | 474 113 |
平均出来高 | 829 708 |
時価総額 | 784.82M |
EPS | $0 ( 2024-03-06 ) |
次の収益日 | ( $-0.850 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.47 |
ATR14 | $0.0110 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Vultaggio Vincent | Sell | 0 | Common Stock |
2024-04-05 | Vultaggio Vincent | Sell | 12 500 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 10 000 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 6 875 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 2 750 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
85.13 |
Last 97 transactions |
Buy: 9 826 125 | Sell: 711 798 |
ボリューム 相関
Zentalis Pharmaceuticals 相関
10 最も正の相関 |
---|
10 最も負の相関 | |
---|---|
RAVN | -0.813 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Zentalis Pharmaceuticals 相関 - 通貨/商品
Zentalis Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2023 |
収益: | $0 |
総利益: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2022 |
収益: | $0 |
総利益: | $-1.43M (0.00 %) |
EPS: | $-4.18 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-5.65 |
Financial Reports:
No articles found.
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。